The Food and Drug Administration (FDA) has approved Tepezza™ (teprotumumab-trbw; Horizon Therapeutics) for the treatment of thyroid eye disease. Tepezza™, a fully human monoclonal antibody, works by binding to insulin-like growth factor 1 receptor and blocking its activation and signaling. The treatment is administered as an intravenous infusion. The approval of Tepezza™ was supported by…
Fresenius Kabi has announced the availability of Levothyroxine Sodium Injection Solution in 100mcg per 5mL, 200mcg per 5mL and 500mcg per 5mL single-dose vials.
Almost all adults with SCH would not benefit from treatment with thyroid hormones
Tirosint-SOL (levothyroxine sodium oral solution) has been made available by IBSA Pharma for the treatment of hypothyroidism and pituitary thyrotropin suppression.
The manufacturing discontinuation was a business decision made by the Company.
Westminster Pharmaceuticals announced a recall of all lots of Levothyroxine and Liothyronine (Thyroid Tablets) 15mg, 30mg, 60mg, 90mg, 120mg as the product was manufactured using active pharmaceutical ingredients (API) from a company that was found to have deviated from the Food and Drug Administration (FDA)’s Good Manufacturing Practices. FDA laboratory tests confirmed Sichuan Friendly Pharmaceutical’s…
In the first 2 years after cancer diagnosis, the excess risk for diabetes was highest, and it remained elevated throughout follow-up.
TransCon PTH is a long-acting prodrug of parathyroid hormone designed to restore PTH to physiologic levels, normalizing blood and urinary calcium levels, serum phosphate levels and bone turnover.
Researchers found that up-front total thyroidectomy was performed in 61% of patients before the 2015 American Thyroid Association guidelines were implemented and in 31.4% after guideline implementation (odds ratio [OR], 0.29).
